Cargando…
Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis
BACKGROUND: Whether the histologic subtype (type 1 and type 2) of papillary renal cell carcinoma (pRCC) is a tool to predict the prognosis is of great debate. This study is aimed to evaluate the prognostic significance of histologic subtype in patients with pRCC after surgery through a systematic re...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421816/ https://www.ncbi.nlm.nih.gov/pubmed/34532250 http://dx.doi.org/10.21037/tau-21-329 |
_version_ | 1783749166689681408 |
---|---|
author | Xiong, Shengwei Zhu, Weijie Li, Xinfei Yu, Yanfei Yang, Kunlin Zhang, Lei Mi, Yue Li, Xuesong Zhou, Liqun |
author_facet | Xiong, Shengwei Zhu, Weijie Li, Xinfei Yu, Yanfei Yang, Kunlin Zhang, Lei Mi, Yue Li, Xuesong Zhou, Liqun |
author_sort | Xiong, Shengwei |
collection | PubMed |
description | BACKGROUND: Whether the histologic subtype (type 1 and type 2) of papillary renal cell carcinoma (pRCC) is a tool to predict the prognosis is of great debate. This study is aimed to evaluate the prognostic significance of histologic subtype in patients with pRCC after surgery through a systematic review and meta-analysis. METHODS: We searched PubMed, the Web of Science, Cochrane library and EMBASE databases to identify studies published until January 20, 2021 according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies were deemed eligible if they compared the overall survival (OS), cancer specific survival (CSS), recurrence-free survival (RFS) or disease-free survival (DFS) between patients with type 1 or type 2 pRCC. And the corresponding hazard ratios (HRs) and 95% conference intervals (CIs) were collected for meta-analysis and further subgroup analysis. RESULTS: Overall 22 studies with a total of 4,494 patients were considered eligible and included for the systematic review and meta-analysis. The pooled results showed that type 2 pRCC was associated with a worse OS (pooled HR 1.61, 95% CI: 1.10–2.36, P=0.02) and CSS (pooled HR 1.59, 95% CI: 1.00–2.51, P=0.05). However, the subgroup analysis yielded the same result as the initial analysis only when the HRs were extracted from univariate analysis. In studies with multivariate analysis, type 2 pRCC was not statistically associated with a worse OS (pooled HR 1.22, 95% CI: 0.97–1.53, P=0.27), CSS (pooled HR 1.16, 95% CI: 0.67–2.00, P=0.60), and DFS (pooled HR 1.33, 95% CI: 0.93–1.91, P=0.12) compared to type 1 pRCC. DISCUSSION: Histologic subtype is not an independent prognostic factor for patients with pRCC, although the result needs to be taken with caution. And studies with retrospective study design, larger sample size and longer follow-up period are required to verify these results. |
format | Online Article Text |
id | pubmed-8421816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-84218162021-09-15 Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis Xiong, Shengwei Zhu, Weijie Li, Xinfei Yu, Yanfei Yang, Kunlin Zhang, Lei Mi, Yue Li, Xuesong Zhou, Liqun Transl Androl Urol Original Article BACKGROUND: Whether the histologic subtype (type 1 and type 2) of papillary renal cell carcinoma (pRCC) is a tool to predict the prognosis is of great debate. This study is aimed to evaluate the prognostic significance of histologic subtype in patients with pRCC after surgery through a systematic review and meta-analysis. METHODS: We searched PubMed, the Web of Science, Cochrane library and EMBASE databases to identify studies published until January 20, 2021 according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies were deemed eligible if they compared the overall survival (OS), cancer specific survival (CSS), recurrence-free survival (RFS) or disease-free survival (DFS) between patients with type 1 or type 2 pRCC. And the corresponding hazard ratios (HRs) and 95% conference intervals (CIs) were collected for meta-analysis and further subgroup analysis. RESULTS: Overall 22 studies with a total of 4,494 patients were considered eligible and included for the systematic review and meta-analysis. The pooled results showed that type 2 pRCC was associated with a worse OS (pooled HR 1.61, 95% CI: 1.10–2.36, P=0.02) and CSS (pooled HR 1.59, 95% CI: 1.00–2.51, P=0.05). However, the subgroup analysis yielded the same result as the initial analysis only when the HRs were extracted from univariate analysis. In studies with multivariate analysis, type 2 pRCC was not statistically associated with a worse OS (pooled HR 1.22, 95% CI: 0.97–1.53, P=0.27), CSS (pooled HR 1.16, 95% CI: 0.67–2.00, P=0.60), and DFS (pooled HR 1.33, 95% CI: 0.93–1.91, P=0.12) compared to type 1 pRCC. DISCUSSION: Histologic subtype is not an independent prognostic factor for patients with pRCC, although the result needs to be taken with caution. And studies with retrospective study design, larger sample size and longer follow-up period are required to verify these results. AME Publishing Company 2021-08 /pmc/articles/PMC8421816/ /pubmed/34532250 http://dx.doi.org/10.21037/tau-21-329 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Xiong, Shengwei Zhu, Weijie Li, Xinfei Yu, Yanfei Yang, Kunlin Zhang, Lei Mi, Yue Li, Xuesong Zhou, Liqun Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis |
title | Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis |
title_full | Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis |
title_fullStr | Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis |
title_full_unstemmed | Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis |
title_short | Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis |
title_sort | whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421816/ https://www.ncbi.nlm.nih.gov/pubmed/34532250 http://dx.doi.org/10.21037/tau-21-329 |
work_keys_str_mv | AT xiongshengwei whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis AT zhuweijie whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis AT lixinfei whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis AT yuyanfei whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis AT yangkunlin whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis AT zhanglei whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis AT miyue whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis AT lixuesong whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis AT zhouliqun whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis |